| Title |
Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)
|
|---|---|
| Published in |
Clinical Cancer Research, June 2021
|
| DOI | 10.1158/1078-0432.ccr-20-5017 |
| Pubmed ID | |
| Authors |
Evanthia T Roussos Torres, Christine Rafie, Chenguang Wang, David Lim, Adam Brufsky, Patricia LoRusso, Joseph Paul Eder, Vincent Chung, Melinda Downs, Molly Geare, Richard Piekarz, Howard Streicher, Leslie Anforth, Michelle A Rudek, Qingfeng Zhu, Sepideh Besharati, Ashley Cimino-Mathews, Robert A Anders, Vered Stearns, Elizabeth M Jaffee, Roisin M Connolly |
X Demographics
The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 16 | 50% |
| Ireland | 3 | 9% |
| United Kingdom | 1 | 3% |
| Unknown | 12 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 63% |
| Scientists | 8 | 25% |
| Practitioners (doctors, other healthcare professionals) | 3 | 9% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 16% |
| Researcher | 4 | 13% |
| Other | 2 | 6% |
| Student > Bachelor | 1 | 3% |
| Student > Master | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 16 | 52% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 26% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Immunology and Microbiology | 2 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Unknown | 17 | 55% |
Attention Score in Context
This research output has an Altmetric Attention Score of 80. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2024.
All research outputs
#531,155
of 25,376,589 outputs
Outputs from Clinical Cancer Research
#284
of 13,231 outputs
Outputs of similar age
#13,185
of 411,664 outputs
Outputs of similar age from Clinical Cancer Research
#12
of 167 outputs
Altmetric has tracked 25,376,589 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,231 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 411,664 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 167 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.